Psychedelic Drugs Market Regional Analsyis

Psychedelic Drugs Market size was valued at USD 2706.71 Million in 2023 and is poised to grow from USD 3066.7 Million in 2024 to USD 7253.41 Million by 2032, growing at a CAGR of 13.3% during the forecast period (2025-2032).

The major players are actively implementing growth strategies, such as product launches, acquisitions, and collaborations, to contribute to the market's growth. For instance, Cybin, a biotechnology company focused on progressing psychedelic therapeutics, announced the launch of the EMBARK psychedelic facilitatory training course in October 2021. This program offers the foundational training required for psychedelic clinical trial facilitators to provide skilled and ethical care to participants receiving psychedelic treatment. 'Pfizer Inc. (USA) ', 'Johnson & Johnson (USA) ', 'AbbVie Inc. (USA) ', 'Jazz Pharmaceuticals (Ireland) ', 'COMPASS Pathways (UK) ', 'MindMed (Canada) ', 'Atai Life Sciences (Germany) ', 'Cybin Corp. (Canada) ', 'Field Trip Health (Canada) ', 'GH Research (Ireland) ', 'Beckley Psytech (UK) ', 'Seelos Therapeutics (USA) ', 'Numinus Wellness Inc. (Canada) ', 'Delix Therapeutics (USA) ', 'Mydecine Innovations Group (Canada) ', 'Revive Therapeutics Ltd. (Canada) ', 'Entheon Biomedical (Canada) ', 'Mind Cure Health Inc. (Canada) ', 'PsyBio Therapeutics (USA) ', 'Tryp Therapeutics (USA) '

Psychedelics have grown in popularity in the last decade because they are used in human mental healing and treatment practices and have the ability to heal the mind. Researchers and scientists are investigating the therapeutic value of psychedelic drugs and compounds that could be a new treatment option for people suffering from depression. Continuous research and development in psychedelic drugs have increased the medication's acceptance. Psychedelic drugs' promising outcomes have increased their use in the United States and other regions, resulting in rising demand for psychedelic drugs; thus, these factors are expected to act as market drivers.

The hospital pharmacy segment is expected to grow over the forecast period due to factors such as increased public awareness of mental health, psychedelic drugs requiring a medical practitioner's prescription, and the use of psychedelic drugs for specific indications, which are driving the growth of hospital pharmacies as distribution channels.

North America is expected to continue to dominate the global psychedelic drugs market during the forecast period. The FDA's recognition of advanced drug fusion portfolios obtained from psychedelic drugs has aided the growth of the North American market. Furthermore, the presence of key market players in this region, as well as increased investment in research and development activities, are supporting market growth. The European Union is the second-largest market after North America in terms of psychedelic drug market share.